EuroELSO Journal Club

Interested in the latest scientific publications?

EURO-ELSO is dedicated to knowledge and education. Therefore, EURO-ELSO Steering Committee has launched the EURO-ELSO Journal Club. We are selecting on a quarterly basis recent interesting ECLS related manuscripts and provided summaries in a concise format. We hope this activity might turn to a useful tool for all physicians and specialists interested in ECLS/ECMO.

On behalf of EURO-ELSO Steering Committee
Jan Belohlavek, Roberto Lorusso, Justyna Swol, Matteo di Nardo and Simon Finney

01 / 2019

Content Overview
Impella and Venoarterial Extracorporeal Membrane Oxygenation (V-A ECMO) Combination Superior to ECMO Alone in Refractory Cardiogenic Shock.
Near-infrared technology can be used for monitoring of distal-limb perfusion in patients on V-A ECMO.
Use of ECMO in Patients with Acute Massive Pulmonary Embolism (PE): Experience from Massachusetts General Hospital, Boston, USA.
Immune response may be positively affected by ECLS intervention.
Venoarterial Extracorporeal Membrane Oxygenation Does not Improve Survival of Children with Severe Septic Shock. Unless They Suffer a Cardiac Arrest.
Unloading the Left Ventricle During Venoarterial Extracorporeal Membrane Oxygenation Therapy in Cardiogenic Shock.
ECMO for refractory cardiogenic shock: patient survival and health-related quality of life.
Preoperative Venoarterial ECMO Slashes Risk Score in Advanced Structural Heart  Disease.
A Single Centre Experience of 900 Interhospital Transports on ECMO.
Extracorporeal life support for refractory cardiac arrest: A 10-year comparative analysis.
Ambulation with Femoral Arterial Cannulation Can be Safely Performed on Veno- Arterial Extracorporeal Membrane Oxygenation.
Outcome after ECMO for the Treatment of High-Risk Pulmonary Embolism: A Multi-Centre Series of 52 Cases.

Impella and Venoarterial Extracorporeal Membrane Oxygenation (V-A ECMO) Combination Superior to ECMO Alone in Refractory Cardiogenic Shock.

Refractory cardiogenic shock can occur after cardiac surgery, as an exacerbation of chronic heart failure with reduced ejection fraction, or from de novo heart failure, most commonly caused by acute coronary syndromes. V-A ECMO might be a game-changer in support of patients in such conditions. Despite being able to offer blood flow of more than 5 L/min of oxygenated blood, VA-ECMO can cause some adverse effects as increased afterload, LV dilation, myocardial ischemia, elevated pulmonary pressures and blood stasis with consecutive thrombus formation. A team of researchers from Ohio, USA, reviewed concomitant use of percutaneous left ventricular decompression with Impella Pump. The largest US-based retrospective study included data collected between 2014 and 2016. Two cohorts of patients were compared – V-A ECMO supported cohort  (n = 36) and ECPELLA cohort supported with a combination of V-A ECMO and Impella (n = 30). The primary outcome was all-cause mortality within 30 days of V-A ECMO implantation. Patients in the ECPELLA cohort experienced a higher incidence of ST-elevation myocardial infarction (STEMI) and percutaneous coronary intervention (PCI), otherwise, the baseline characteristics were similar.

Thirty-day all-cause mortality was significantly lower in the ECPELLA cohort (57% vs. 78%; hazard ratio [HR] 0.51 [0.28–0.94], log rank p = 0.02), and this difference remained intact after correcting for STEMI and PCI. The secondary outcomes, including duration of support, stroke, major bleeding, hemolysis, and cardiac recovery, were comparable between the cohorts. The only difference was found in an inotropic score, which was greater in the V-A ECMO group by day 2 (11 vs. 0; p = 0.001). The addition of Impella to V-A ECMO for patients with refractory cardiogenic shock was associated with lower all-cause 30-day mortality, lower inotrope use, and comparable safety profiles as compared with V-A ECMO alone. 

Bottom Line: The study, therefore, suggests that the addition of Impella to V-A ECMO is associated with improved survival in this clinical setting. Randomized controlled trials are required to confirm these findings.

Patel, Sandeep M., et al. “Simultaneous Venoarterial Extracorporeal Membrane Oxygenation and Percutaneous Left Ventricular Decompression Therapy with Impella Is Associated with Improved Outcomes in Refractory Cardiogenic Shock.” ASAIO Journal, vol. 65, no. 1, 2019, pp. 21–28., doi:10.1097/mat.0000000000000767.

Near-infrared technology can be used for monitoring of distal-limb perfusion in patients on V-A ECMO.

V-A ECMO is still associated with a relatively high incidence of vascular complications and especially femoral cannulation increases the risk of lower-limb hypoperfusion and ischemia. Those can lead to severe irreversible conditions, including a limb loss. Although clinical evaluation of the perfusion is recommended, technological advances offer comprehensive and quantitative monitoring. A team from the Columbia University Medical Center in New York, USA, evaluated use of non-invasive lower-limb oximetry, using near-infrared reflectance spectroscopy (NIRS) in this clinical setting.

Data were collected from 25 patients (age 22-78) receiving femoral V-A ECMO between June 2016 and January 2017. Subjects were continuously monitored using the CASMED Fore-Sight Elite tissue oximeter. A retrospective pilot study was conducted to review the correlation between NIRS tissue saturations (StO2) and clinical indications of limb ischemia. Evaluated events included StO2s less than 50% for more than four minutes or StO2 differentials between the cannulated and non-cannulated legs greater than 15%.

Clinical signs of lower-limb ischemia, e.g. cold limb, mottled skin and absent Doppler signal, were observed in six patients from the group. All of those events were matched with StO2s below 50% that persisted for longer than four minutes. One patient had a false-positive device indication of hypoperfusion with StO2 below 50% for more than four minutes due to a venous saturation below 30% without the localized clinical counterpart and another had a false-positive absent Doppler signal caused by high doses of vasopressors. Five patients had StO2s below 50% for less than four minutes and none of these patients had clinical indications of lower-limb hypoperfusion, suggesting the importance of a time frame. Cannula-related obstruction of flow to the distal portion of the leg was associated with StO2 differentials greater than 15% in all affected patients and conversely no patients without cannula-related obstruction to flow had StO2 differentials greater than 15%. Sensitivity and specificity were 100% for diagnosing cannula-related obstruction to flow when the StO2 in the cannulated leg was below 50% for longer than four minutes and a differential between the cannulated and non-cannulated legs was greater than 15%. This has made NIRS monitoring especially valuable during the initiation of ECMO with femoral cannulation and for the period immediately following initiation when these patients are at the greatest risk for developing lower-limb ischemia.

Bottom line: Continuous NIRS monitoring might be used in the future as a warning system for identifying lower-limb ischemia and can also increase the confidence of bedside support staff to care for ECMO patients.

Patton-Rivera, Killian, et al. “Using near-Infrared Reflectance Spectroscopy (NIRS) to Assess Distal-Limb Perfusion on Venoarterial (V-A) Extracorporeal Membrane Oxygenation (ECMO) Patients with Femoral Cannulation.” Perfusion, vol. 33, no. 8, 2018, pp. 618–623., doi:10.1177/0267659118777670.

Use of ECMO in Patients with Acute Massive Pulmonary Embolism (PE): Experience from Massachusetts General Hospital, Boston, USA.

ECMO has been used to stabilize patients with acute PE in order to prolong valuable time for possible interventions, such as systemic thrombolysis, catheter-directed therapy or surgical embolectomy. Because these patients are often too unstable to transfer to the operating room or catheterization laboratory, a bridge to definitive therapy is needed (bridge-to-advanced therapy). The recommendation of the European Society of Cardiology for ECMO in the setting of a massive PE is based on case reports and case series and, therefore, is not assigned a class or level of evidence. Moreover, the latest American Heart Association scientific statement on the management of PE did not include the use of ECMO, citing a lack of data. At the current time, decisions need to be made on a case-by-case basis. However, one of the new additions to the slowly growing evidence in this clinical setting is a case series and review of the literature, published in Perfusion journal in December last year. A consecutive cohort of patients with confirmed PE was described in a pulmonary embolism response team (PERT) registry. Data were captured prospectively for up to one year of follow-up.

In total, 13 patients were identified, with the mean age of 49 ± 19 years, 46% were female. All of them experienced a cardiac arrest, either as an initial presentation or as in-hospital event. Right ventricular (RV) dilation on echocardiogram with RV hypokinesis was present in the whole cohort. 62% of subjects received systemic thrombolysis with intravenous tissue plasminogen activator (tPA), 23% underwent catheter-directed thrombolysis therapy using the EKOS system and 31% underwent surgical embolectomy. Mean ECMO duration was 5.5 days, ranging from 2-18 days. Thirty-day mortality was 31% and one-year mortality was 54%. The majority of patients treated with ECMO after PE in the PERT registry cohort series survived for 30 days, despite the fact that most had suffered at least one cardiac arrest event.

Bottom line: Although ECMO may be helpful in many patients who have a low chance of surviving massive PE without hemodynamic support, it does come with complications, in particular, major bleeding, that was suffered by 54% of patients from the PERT registry.

Al-Bawardy, Rasha, et al. “Extracorporeal Membrane Oxygenation in Acute Massive Pulmonary Embolism: a Case Series and Review of the Literature.” Perfusion, vol. 34, no. 1, 2018, pp. 22–28., doi:10.1177/0267659118786830.

Immune response may be positively affected by ECLS intervention.

Use of extracorporeal life support (ECLS) has a major impact on a physiological systemic response and organ function of the organism. However, whether use of ECLS results in immune dysregulation of an innate immune response remains unclear. Animal studies demonstrate that exposure of blood to the ECLS circuit induces an inflammatory response, but its extent in humans has not been yet well described. The team based mostly at the University of Michigan, USA, obtained blood samples from a total of 19 patients, 7 adults and 12 children, before, during, and after ECLS. Median ECLS duration was 10 days (range: 3–108) and nine patients died during the ICU stay. A function of the innate immune system was measured by ex vivo lipopolysaccharide (LPS)-induced tumor necrosis factor-α (TNF-α) and plasma cytokine levels (interleukin [IL]- 6, IL-8, IL-10, and TNF-α). Immunoparalysis was defined as ex vivo TNF-α levels less than 200 pg/ml. After stratifying the cohort by the presence of immunoparalysis before ECLS, those immunoparalyzed showed increased response to LPS on days 1 and 3 (p = 0.016). Those without pre-ECLS immunoparalysis showed a transient decrease in response on day 3 (p = 0.008). Plasma IL-10 levels were elevated in those with pre-ECLS immunoparalysis and dropped significantly by day 1 (p = 0.031). The number treated with steroids was similar in the two groups.

In summary, the study demonstrated that patients who were immunoparalyzed before going on ECLS showed a gradual increase in levels of innate immune function (as indicated by increased ex vivo TNF-α production) over time. This increased responsiveness may be secondary to the decrease in the anti-inflammatory cytokine IL-10 between ECLS initiation and day 1, or could be due to the better oxygen delivery to different vital organs including the immune system. In addition, the data also showed a transient drop in innate immune system responsiveness in the group without pre-ECLS immunoparalysis.

Bottom line: These data suggest that the responsiveness of the immune system is changing during ECLS and that there exists a critical need for larger studies designed to obtain a more complete understanding of the relationship among ECLS, inflammation, and the immune system.

Beshish, Asaad G., et al. “The Functional Immune Response of Patients on Extracorporeal Life Support.” ASAIO Journal, vol. 65, no. 1, 2019, pp. 77–83., doi:10.1097/mat.0000000000000748.

Venoarterial Extracorporeal Membrane Oxygenation Does not Improve Survival of Children with Severe Septic Shock. Unless They Suffer a Cardiac Arrest.

The role of V-A ECMO in severe pediatric septic shock remains controversial. Maintaining circulatory failure in a severe septic shock is challenging. However, whether the benefits of V-A ECMO outweigh the risks remains to be determined. The analysis by a multinational team led from Melbourne, Australia, represents the largest cohort study comparing extracorporeal circulatory support and conventional therapy in severe pediatric sepsis. Newly published data from a prospective cohort study followed a total of 164 children admitted to intensive care between the years 2006 and 2014. Children aged 30 days and more were treated in tertiary PICUs in Australia, New Zealand, the Netherlands, United Kingdom, and the United States. Majority of subjects was receiving conventional therapy only (n = 120), V-A ECMO was used in approximately one quarter (n = 44). Although the survival rate demonstrated the trend of superiority in V-A ECMO group (50 vs. 40%), it did not reach the statistical significance (p = 0.25; CI, –0.3 to 0.1). However, in children who suffered an in-hospital cardiac arrest, survival to hospital discharge was 18% with conventional therapy and 42% with V-A ECMO (p = 0.02; CI, 2.5–42%).  In this scenario, extracorporeal cardiorespiratory support was associated with a 24% survival advantage. Moreover, survival was significantly higher in patients who received ECMO flows higher than 150mL/kg/min compared with children who received standard flows or no ECMO (82%, 43%, and 48%; p = 0.03; CI, 0.1–0.7 and p < 0.01; CI, 0.2–0.7, respectively). The survival rate of children who received these very high-flow rates in two of the seven participating PICUs was almost 50% higher that seen in all other patients in the study, which supports the suggestion that maximizing extracorporeal circulatory output is fundamental to survival.

Lengths of ICU and hospital stay were significantly longer for children who had V-A ECMO, but this association was not present in survivors, indicating that VA ECMO resulted in non-survivors being kept alive for longer.

Bottom line: Based on these results, V-A ECMO did not appear to offer an advantage over conventional therapy but increased ICU and hospital resource use. However, this negative finding should be treated with some caution. Despite failing to reach statistical significance, the absolute difference in mortality of 10% between the two cohorts may be deemed clinically important, particularly in light of the study’s limits with regard to sample size and the relatively wide CI.

Oberender, Felix, et al. “Venoarterial Extracorporeal Membrane Oxygenation Versus Conventional Therapy in Severe Pediatric Septic Shock.” Pediatric Critical Care Medicine, 2018, p. 1., doi:10.1097/pcc.0000000000001660.

Unloading the Left Ventricle During Venoarterial Extracorporeal Membrane Oxygenation Therapy in Cardiogenic Shock.

The use of LV unloading in V-A ECMO patients is controversial and currently a matter of a thorough debate. The implementation of percutaneous LV unloading modalities is obviously attractive and apparently efficient, although costs and peculiar adverse events may undermine its utilization. Axial continuous flow and transaortic devices may represent an advanced modality of combined LV unloading and circulatory support, making V-A ECMO + transaortic suction device an intriguing association for patients supported in cardiogenic shock.

The series of 106 patients from Hamburg is extremely interesting since reports about a robust clinical experience but shed some light also on the beneficial effects of the combination of assist systems.

Successful weaning was achieved in almost 52% of the patients, with a survival to discharge of 35.8%, which was higher than the predicted SAVE score (20%).
The performance of right heart catheterization clearly indicated a marked reduction of pulmonary capillary wedge pressure after the introduction of the transaortic device during the V-A ECMO run.

Bottom line: From this series, it appears that the combination of LV unloading with V-A ECMO is beneficial. However, the ultimate impact of such an association with respect to patient survival remains to be elucidated

Schrage, Benedikt, et al. “Unloading of the Left Ventricle During Venoarterial Extracorporeal Membrane Oxygenation Therapy in Cardiogenic Shock.” JACC: Heart Failure, vol. 6, no. 12, 2018, pp. 1035–1043., doi:10.1016/j.jchf.2018.09.009.

ECMO for refractory cardiogenic shock: patient survival and health-related quality of life.

One of the most important controversies and a major limiting factor of ECMO use, particularly in relation to venoarterial support for cardiogenic shock and cardiac arrest, relates to the long-term results. A single-center study by Finnish authors assessed retrospectively 133 V-A ECMO patients with a follow-up of 10 years. Overall, almost 50% of the subjects were successfully weaned from ECMO, whereas 12% were bridged to heart transplantation, 11.3% to a ventricular assist device, and 0.8% to total artificial heart. Survival to discharge was 64%. A short Form Health Survey was also conducted among hospital survivors, and findings showed better emotional well-being and equal energy, pain and general health perception as compared to the general population. Limitations were perceived only in physical health with 56% of the patients younger than 60 years returning to work.

Bottom line: This single-center series provides an interesting picture of the in-hospital outcome, particularly in relation to the access to more advanced circulatory and heart therapies. Favorable post-discharge quality of life was noticed, slightly in contrast with previous publications showing a high impact on neuro-psychological and physical aspects of ECMO survivors.

Jäämaa-Holmberg, Salla, et al. “Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock: Patient Survival and Health-Related Quality of Life.” European Journal of Cardio-Thoracic Surgery, 2018, doi:10.1093/ejcts/ezy374.

Preoperative Venoarterial ECMO Slashes Risk Score in Advanced Structural Heart  Disease

 The concept of “prophylactic ECMO” to improve critical preoperative modalities is not new and can be used in order to enhance perioperative course and outcome. This limited series of 12 patients in cardiogenic shock, who were evaluated for cardiac surgery, shows how the use of peripheral ECMO in the presence of a surgical diagnosis may significantly improve the preoperative conditions. Only 1 patient did not proceed to surgical correction of the underlying cardiac disease because of unknown anoxic brain injury. All the remaining patients survived to hospital discharge, with 2 death in the post-discharge period (at 76 and 230 days respectively) and with 6 patients surviving over 1 year.

 This outstanding experience, in patients who would otherwise have been excluded from surgery or most likely, would have a very complicated course and high perioperative mortality, confirm that ECMO may be effective. It could be used as a prophylactic tool to improve overall and organ conditions, enhance perioperative ICU stay, and successfully lead the patient to discharge with limited complications (in this series only 1 permanent stroke).

Bottom Line: ECMO can be used as a bridge-to-surgery in patients with mechanical complications of acute myocardial infarction and decompensated valvular disease in the presence of general conditions, which otherwise would define these patients inoperable or to transition patients from rescue to elective operation.

Watkins, A. Claire, et al. “Preoperative Venoarterial Extracorporeal Membrane Oxygenation Slashes Risk Score in Advanced Structural Heart Disease.” The Annals of Thoracic Surgery, vol. 106, no. 6, 2018, pp. 1709–1715., doi:10.1016/j.athoracsur.2018.07.038.

A Single Centre Experience of 900 Interhospital Transports on ECMO

This retrospective study analyzed the very unique experience of the Karolinska hospital during a 21-year period. 908 patients were transported to the Stockholm hospital. Severe complications occurred in 20% of the patients, strongly associated with V-A configuration and fixed-wing transport. The occurrence of severe complications was not, however, associated with increased mortality. On-transport mortality occurred in only 2 patients.

 Bottom line: ECMO patient transport is a complex and dangerous situation. This unique series, however, demonstrates how experience and organization may allow a very safe provision of such a service, which, unfortunately, is not void of unexpected and dangerous events. Fatal cases were fortunately rare and severe complications were not associated with dismal outcome.

Fletcher-Sandersjöö, Alexander, et al. “A Single-Center Experience of 900 Interhospital Transports on Extracorporeal Membrane Oxygenation.” The Annals of Thoracic Surgery, vol. 107, no. 1, 2019, pp. 119–127., doi:10.1016/j.athoracsur.2018.07.040.

Extracorporeal life support for refractory cardiac arrest: A 10-year comparative analysis

 ECMO is routinely used to treat patients after cardiac arrest. This study of French authors analyzed a single-center experience with ECMO used in the setting of in-hospital (IHCA) and out-of-hospital (OHCA) cardiac arrests during a 10-year period. In total, 45 (34,4%) IHCA and 86 (65.6%) OHCA cases were included, mean age was 43.2 years and 72% were male. Patient profiles were comparable with an obvious exception of no flow and low-flow times, reaching 85.3 minutes in the OHCA group.

82.4% of the patients died on ECMO (79% for IHCA and 84% in OHCA, no significant difference). Also, the neurologic outcome at hospital discharge was not different between groups, and the presence of shockable rhythm was associated with better outcome.

 Bottom line: The study shows that even with appropriate ECMO program organization, the outcome of IHCA and OHCA do not differ. Another important issue, however, accounts for futile interventions which, for the time being, represent the major issue in this setting

 Pozzi, Matteo, et al. “Extracorporeal Life Support for Refractory Cardiac Arrest: A 10-Year Comparative Analysis.” The Annals of Thoracic Surgery, vol. 107, no. 3, 2019, pp. 809–816., doi:10.1016/j.athoracsur.2018.09.007.

Ambulation with Femoral Arterial Cannulation Can be Safely Performed on Veno- Arterial Extracorporeal Membrane Oxygenation

Prolonged bed rest may lead to a deterioration in an overall physical condition. The retrospective study of the authors from the University of Maryland School of Medicine assessed the feasibility and outcome of patients cannulated for V-A ECMO peripherally, who were able to ambulate. Among 104 patients submitted to V-A ECMO in a 2-year period, 15 were able to ambulate at least once while on support. In 46% of the patients, the indication was decompensated heart failure, in 54% acute pulmonary embolism and 26% of the group had V-A ECMO during CPR. Mean time from ECMO implant-to-ambulation was 4 days (range 1-42 days) with a mean post-cannulation walking distance of 300 feet. No complication or dysfunction regarding patient-related or device-related function and state was observed. One-year survival was 100% for this patient group

Bottom line: This limited series demonstrates that peripheral ECMO with femoral cannulation does not preclude active movement and ambulation. In selected patients, this objective might be pursued and does not apparently induce any major complications

Pasrija, Chetan, et al. “Ambulation with Femoral Arterial Cannulation Can Be Safely Performed on Veno-Arterial Extracorporeal Membrane Oxygenation.” The Annals of Thoracic Surgery, 2018, doi:10.1016/j.athoracsur.2018.10.048.

Outcome after ECMO for the Treatment of High-Risk Pulmonary Embolism: A Multi-Centre Series of 52 Cases.

Use of ECMO in the setting of a high-risk pulmonary embolism remains controversial. This multicenter study followed 180 patients over a period of 2 years, data were analyzed retrospectively. 128 patients were treated without ECMO, circulatory support was used in 52 subjects. Overall 30-day mortality was 48.3% with 43% in those treated without ECMO, and 61.5% in those with ECMO. In the patients who underwent ECMO+ fibrinolysis 30-day mortality was 76.5%, whereas 29.4% was the mortality for patients with ECMO +embolectomy, and 77.7% for those who had ECMO alone. In the patients who received ECMO, 38.5% had a major in-hospital bleeding event, without significant difference across groups.

The authors stated that based on the results, stand-alone ECMO does not appear as an effective strategy in this clinical setting. However, the combination of ECMO and surgical embolectomy provided a high success rate and might be the subject of dedicated investigation, especially with regards to recent favorable series.

 Bottom line: Apparently the use of ECMO in acute pulmonary embolism may account for significant mortality as compared to medical treatment alone. But, obviously, the patients undergoing ECMO were in more critical conditions and often after a cardiac arrest.

Meneveau, Nicolas, et al. “Outcomes after Extracorporeal Membrane Oxygenation for the Treatment of High-Risk Pulmonary Embolism: a Multicentre Series of 52 Cases.” European Heart Journal, vol. 39, no. 47, 2018, pp. 4196–4204., doi:10.1093/eurheartj/ehy464.